Search

Your search keyword '"Colin Laurence"' showing total 153 results

Search Constraints

Start Over You searched for: Author "Colin Laurence" Remove constraint Author: "Colin Laurence"
153 results on '"Colin Laurence"'

Search Results

1. Evaluating the impacts of major transportation disruptions – San Francisco Bay Area case study

2. DNA cytosine methylation in the Bovine Leukemia Virus promoter is associated with latency in a Lymphoma-derived B-cell line : potential involvement of direct inhibition of CREB/CREM/ATF binding

4. Molecular control of HIV-1 postintegration latency: implications for the development of new therapeutic strategies

7. First-in-human clinical trial to assess pharmacokinetics, pharmacodynamics, safety, and tolerability of iscalimab, an anti-CD40 monoclonal antibody

8. Prevalence of rheumatic heart disease in Zambian school children

13. The chromatin remodelling protein LSH/HELLS regulates the amount and distribution of DNA hydroxymethylation in the genome

15. The chromatin remodelling protein LSH/HELLS regulates the amount and distribution of DNA hydroxymethylation in the genome.

20. A Multicentre, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy, Safety, and Tolerability of the S1P Receptor Agonist KRP203 in Patients with Moderately Active Refractory Ulcerative Colitis

22. Designing for Mode Shift Opportunity with Metropolitan Scale Simulation

23. Dispersion compensation by a liquid lens (DisCoBALL)

24. 10.1177_1358863X19859072_supplementary_material – Supplemental material for A randomized, placebo-controlled trial of canakinumab in patients with peripheral artery disease

25. How Often Do Safety Signals Occur by Chance in First-in-Human Trials?

27. A randomized, placebo-controlled trial of canakinumab in patients with peripheral artery disease

31. Implication of the pol gene intragenic enhancer in the cellular specificity of Human Immunodeficiency Virus type 1 (HIV-1) gene expression

32. Implication of the HIV-1 pol gene intragenic enhancer in myeloid-specific viral gene expression

33. Implication of the pol gene intragenic enhancer in the cellular specificity of HIV-1 gene expression

34. Epidemiology of pharyngitis as reported by Zambian school children and their families: implications for demand-side interventions to prevent rheumatic heart disease

35. Abstract 11: Effects of Canakinumab in Patients With Peripheral Artery Disease

37. Characterization of the HIV-1 cis-regulatory intragenic region

38. Characterization of the HIV-1 cis-regulatory intragenic region

39. Tuning of AKT-pathway by Nef and its blockade by protease inhibitors results in limited recovery in latently HIV infected T-cell line.

40. Tuning of AKT-pathway by Nef and its blockade by protease inhibitors results in limited recovery in latently HIV infected T-cell line

41. 5-hydroxymethylcytosine marks promoters in colon that resist DNA hypermethylation in cancer.

42. Prevalence of rheumatic heart disease in Zambian school children.

43. Régulation transcriptionelle et épigénétique de l'expression des rétrovirus HIV-1 et BLV

44. Molecular control of gene expression in the HIV-1 and BLV retroviruses/ Régulation transcriptionelle et épigénétique de l'expression des rétrovirus HIV-1 et BLV

45. Long-term effects of secukinumab on MRI findings in relation to clinical efficacy in subjects with active ankylosing spondylitis: an observational study

46. DNA Cytosine Methylation in the Bovine Leukemia Virus Promoter Is Associated with Latency in a Lymphoma-derived B-cell Line: POTENTIAL INVOLVEMENT OF DIRECT INHIBITION OF cAMP-RESPONSIVE ELEMENT (CRE)-BINDING PROTEIN/CRE MODULATOR/ACTIVATION TRANSCRIPTION FACTOR BINDING*

47. 5-hydroxymethylcytosine marks promoters in colon that resist DNA hypermethylation in cancer

48. DNA cytosine methylation in the bovine leukemia virus promoter is associated with latency in a lymphoma-derived B-cell line: Potential involvement of direct inhibition of CREB/CREM/ATF transcription factor binding

49. HIV-1 chromatin, transcription, and the regulatory protein tat

50. A 24-month open-label study of canakinumab in neonatal-onset multisystem inflammatory disease

Catalog

Books, media, physical & digital resources